# Napkin AI Content - Western Region Growth Strategy

Instructions: Copy each section into Napkin AI separately, click "Generate Visual", select the best option.

---

## 1. TERRITORY ENGINE - "Pistons in the Regional Engine"

The Western Region operates like an engine with 4 pistons firing in sequence:

**BIOTECH BEACH (San Diego)**
- Revenue: $7.98M | GP: 70.8%
- Pipeline: $7.9M
- Status: PROTECT - High performance

**LA BIOMED (Los Angeles)**  
- Revenue: $6.47M | GP: 23.9%
- Pipeline: $1.61M
- Status: FIX MARGINS - 4 problem accounts

**BIOTECH BAY (San Francisco)**
- Revenue: $1.35M | GP: 36.2%
- Pipeline: $1.09M
- Status: HIRE AE - Underpenetrated

**CASCADIA (Seattle)**
- Revenue: $0.60M | GP: 43.4%
- Pipeline: $0
- Status: PARTNER FIRST - Zero presence

---

## 2. PARTNER CHANNEL GAP

USDM Partner Revenue Share: 1.1%
Industry Average (2025): 28%
Top Performers: 58%

THE GAP: 27 percentage points behind industry

Partner-sourced deals deliver:
- 40% higher deal value
- 53% better close rates
- 46% faster sales cycles
- 72% lower customer acquisition cost

Current partner pipeline: $606K
Target partner pipeline: $4.8M (10% of West)

---

## 3. SELLER PERFORMANCE VARIANCE

Western Region Seller Win Rates:

TOP PERFORMER:
Justin Ott - EVP West
Win Rate: 60.9%
Pipeline: $6.9M
Status: STAR

NEEDS COACHING:
Mike Campbell - LA BioMed
Win Rate: 38.2%
Pipeline: $2.9M
Status: COACHING

CRITICAL CONCERN:
Kim Guihen - Partner Lead
Win Rate: 7.5%
Pipeline: $70K
Status: ROLE REVIEW

Performance variance: 8.1x between best and worst
Company average: 41.6%

---

## 4. PIPELINE COVERAGE CRISIS

Current Pipeline: $14.05M
Target Revenue: $17M (estimated)
Coverage Ratio: 0.82x

HEALTHY TARGET: 3.0x coverage
GAP: 2.18x short

Pipeline Age Breakdown:
- Healthy (under 90 days): 23% - $3.2M
- Aging (90-180 days): 29% - $4.1M  
- STALE (180+ days): 48% - $6.75M

WARNING: Nearly half of pipeline is over 180 days old
This is CRM hygiene failure, not real pipeline

---

## 5. MARGIN EROSION - THE LA PROBLEM

4 accounts dragging West GP from 50% to 36.5%:

GILEAD SCIENCES
Revenue: $2.13M | GP: 22% | Trend: Expanding

KITE PHARMA
Revenue: $2.08M | GP: 20% | Trend: Expanding

AMGEN
Revenue: $1.75M | GP: 21% | Trend: Stable

ENOVIS
Revenue: $773K | GP: 18% | Trend: Growing fast

Total Problem Revenue: $6.73M (42% of West)
Blended Problem GP: 20.5%

CONTRAST - Star Accounts:
Crinetics: 40.9% GP
Arrowhead: 40.1% GP
Harmony Bio: 93.1% GP

---

## 6. GTM PRIORITIZATION - FROM 13 TO 5

CURRENT STATE: 13 GTM Pillars
Too many for 2 quota-carrying sellers
13 pillars รท 2 sellers = Strategic sprawl

RECOMMENDED TOP 5 FOCUS:

1. CLOUD MIGRATION + VALIDATION
   Why: AWS/Azure partnerships, clear ROI

2. AI GOVERNANCE
   Why: Emerging need, limited competition

3. CELL THERAPY MANUFACTURING QA
   Why: San Diego cluster strength

4. DATA INTEGRITY REMEDIATION
   Why: FDA pressure driving demand

5. CSV FOR SAAS
   Why: Veeva/Box partnerships, recurring

DEPRIORITIZE: Lab informatics, training, staff aug, audit support

---

## 7. THE TURNAROUND REALITY

This is NOT a growth strategy.
This is a TURNAROUND.

REVENUE: Down 18% year-over-year
WIN RATE: Down from 52% to 41.6% (-11 points)
EXPANSION: 35.6% win rate on existing customers
NEW LOGO: 90.2% win rate (healthy)

KEY INSIGHT:
We're better at landing new customers than keeping them.
This is backwards.

CHALLENGES:
- Revenue declining
- Win rates falling
- Expansion struggling
- Pipeline stale
- Margins eroding
- Seller concentration risk

---

## 8. PARTNER INVESTMENT ROI

THE ASK: $300K Total Investment

BY TERRITORY:
- Biotech Beach: $50K (cell therapy partners)
- LA BioMed: $25K (vendor programs)
- Biotech Bay: $75K (VC ecosystem)
- Cascadia: $150K (partner-first entry)

EXPECTED RETURN:
Partner Pipeline: $4.8M
ROI Multiple: 16x

2026 TARGET:
Partner share of West: 10% (up from 1.1%)
Active partnerships: 5+ (up from 3)
Partner win rate: 45%+ (up from 22.5%)

---

## EXPORT SETTINGS

For each infographic:
- Export as PNG (high resolution)
- Use consistent color scheme (dark blues, greens, reds for warnings)
- Include USDM branding where possible
